Association between lorlatinib blood concentration and adverse events and clinical impact of dose modification. - Igawa Y; Yoshida T; Makihara R; Torasawa M; Tateishi A; Matsumoto Y; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Yamamoto N; Ohe Y (Lung cancer (Amsterdam, Netherlands), 2024)